Effects of Inhaled Corticosteroid/long-acting beta-2 Agonist Combination on the Airway Microbiome of Patients with COPD: A Randomized Controlled Trial (DISARM)

CONCLUSIONS: Fluticasone-based ICS/LABA therapy modifies the airway microbiome in COPD, leading to a relative reduction in alpha diversity and a greater number of bacterial taxa changes. These data may have implications in patients who develop pneumonia on ICS. Clinical trial registration available at www.clinicaltrials.gov, ID:NCT02833480.PMID:34464242 | DOI:10.1164/rccm.202102-0289OC

Source: Am J Respir Crit Car... - August 31, 2021 Category: Intensive Care Authors: Fernando Sergio Leitao Filho Hiroto Takiguchi Kentaro Akata Seung Won Ra Ji-Yong Moon Hyun Kuk Kim Yuji Cho Kei Yamasaki Stephen Milne Julia Yang Cheng Wei Tony Yang Xuan Li Corey Nislow Stephan F van Eeden Tawimas Shaipanich Stephen Lam Janice M Leung Do Source Type: research